Protelos, first in new class of osteoporosis therapies launched today

Protelos (strontium ranelate), the only osteoporosis therapy to simultaneously increase bone formation and decrease bone resorption, was launched today by Servier Laboratories. The first in a new class of osteoporosis therapies called dual action bone agents (DABAs), Protelos is licenced for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fracture.

Recent Blog Post

Celebrating International Women's Day: Stories from Twins and TwinsUK Staff

25th March 2024 – by Aaruthy Suthahar International Women’s Day (IWD) on March 8th is a day to celebrate the...

TwinsUK part of team awarded £20 million to study bowel cancer

7th March 2024 – by TwinsUK and King’s College London TwinsUK will receive part of £20m in funding by Cancer...

Daily fibre supplement improves older adults’ brain function in just 12 weeks

29th February 2024 – By Aaruthy Suthahar Researcher’s from TwinsUK conducted a study on twins aged 60 and above has...